Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
NCT03042325
·
clinicaltrials.gov ↗
PHASE4
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Business decision, no safety or efficacy concerns
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:
Alogliptin
Sponsor
Takeda